New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
16:18 EDTVNDAVanda withdraws Marketing Authorization Application for Fanaptum in EU
Vanda Pharmaceuticals announced that it has withdrawn its Marketing Authorization Application submitted to the European Medicines Agency's Committee for Medicinal Products for Human Use for Fanaptum for the treatment of adult patients with schizophrenia. This withdrawal is based on a request by the CHMP/Rapporteur/Co-rapporteur for Vanda to submit the results from an ongoing relapse prevention, randomized iloperidone-placebo withdrawal study in patients with schizophrenia. The results of this study will not be available in the timeframe allowed in the Centralised Procedure. Vanda intends to reassess its European regulatory strategy for Fanaptum once the results from the Relapse Prevention Study in Patients with Schizophrenia become available.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
11:48 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
October 29, 2014
09:01 EDTVNDAVanda 4M share Spot Secondary priced at $11.60
Subscribe for More Information
October 28, 2014
16:02 EDTVNDAVanda files to sell common stock, no amount given
Jefferies LLC and Piper Jaffray & Co. are acting as the joint book-running managers for the offering.
08:05 EDTVNDAPressure on Vanda unwarranted, says JMP Securities
After Vanda reported stronger than expected Q3 results, JMP Securities thinks the pressure on the stock is disconnected from the company's strong Helioz launch. The firm keeps a $30 price target and Outperform rating on the shares.
October 27, 2014
09:14 EDTVNDAOn The Fly: Pre-market Movers
Subscribe for More Information
07:18 EDTVNDAVanda reports Q3 total operating expenses $16.2M compared to $14.1M a year ago
07:17 EDTVNDAVanda cuts FY14 operating expenses to $105M-$110M from $110M-$120M
Subscribe for More Information
07:17 EDTVNDAVanda reports Q3 Hetlioz US sales grew to $5.2M
Subscribe for More Information
07:16 EDTVNDAVanda reports Q3 EPS (4c), consensus (39c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use